3-氯-4,6-二甲基哒嗪 | 17258-26-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 3-氯-4,6-二甲基哒嗪
• 英文名称: 3-chloro-4,6-dimethylpyridazine
• 英文别名: 3-Chlor-4,6-dimethyl-pyridazin
• CAS: 17258-26-3
• 化学式: C₆H₇ClN₂
• 分子量: 142.588
• InChiKey: CIBIWQSBPWNHNJ-UHFFFAOYSA-N

物化性质

• 熔点：
  98-100 °C
• 沸点：
  272.0±35.0 °C(Predicted)
• 密度：
  1.184±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-氯-4,6-二甲基哒嗪 在 Pd/SrCO₃ 、 氨 作用下， 生成 3,5-dimethyl-pyridazine
  参考文献：
  名称：

  Levisalles, Bulletin de la Societe Chimique de France, 1957, p. 1009,1011

  摘要：

  DOI：
• 作为产物：
  描述：

  2-羟基-2-甲基乙酰丙酸 在 一水合肼 、 三氯氧磷 作用下， 以 正丁醇 为溶剂， 生成 3-氯-4,6-二甲基哒嗪
  参考文献：
  名称：

  3-Aminopyridazine derivatives with atypical antidepressant, serotonergic and dopaminergic activities

  摘要：

  Minaprine [3-[(beta-morpholinoethyl)amino]-4-methyl-6-phenylpyridazine dihydrochloride] is active in most animal models of depression and exhibits in vivo a dual dopaminomimetic and serotoninomimetic activity profile. In an attempt to dissociate these two effects and to characterize the responsible structural requirements, a series of 47 diversely substituted analogues of minaprine were synthesized and tested for their potential antidepressant, serotonergic, and dopaminergic activities. The structure-activity relationships show that dopaminergic and serotonergic activities can be dissociated. Serotonergic activity appears to be correlated mainly with the substituent in the 4-position of the pyridazine ring whereas the dopaminergic activity appears to be dependent on the presence, or in the formation, of a para-hydroxylated aryl ring in the 6-position of the pyridazine ring.

  DOI：

  10.1021/jm00123a004

文献信息

• METALLOENZYME INHIBITOR COMPOUNDS
  申请人：Viamet Pharmaceuticals (NC), Inc.

  公开号：US20180185362A1

  公开（公告）日：2018-07-05

  Provided are compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.

  提供具有金属酶调节活性的化合物，以及通过这些金属酶介导的治疗疾病、紊乱或症状的方法。
• [EN] OGA INHIBITOR COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS D'OGA
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2019243530A1

  公开（公告）日：2019-12-26

  The present invention relates to O-GIcNAc hydrolase (OGA) inhibitors having the structure shown in formula (I). The invention is also directed to pharmaceutical compositions comprising such compounds to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C90RF72 mutations. wherein RB is an aromatic heterobicyclic radical selected from the group consisting of (b-1) to (b-6).

  本发明涉及具有式(I)所示结构的O-GIcNAc水解酶（OGA）抑制剂。该发明还涉及包含这种化合物的药物组合物、制备这种化合物和组合物的方法，以及利用这种化合物和组合物预防和治疗抑制OGA有益的疾病，如tau病变，特别是阿尔茨海默病或进行性上核性麻痹；以及伴有tau病理的神经退行性疾病，特别是由C90RF72突变引起的肌萎缩侧索硬化或额颞叶痴呆症。其中RB是从（b-1）到（b-6）组成的芳香杂双环基团。
• CGRP ANTAGONISTS
  申请人：Gottschling Dirk

  公开号：US20110059954A1

  公开（公告）日：2011-03-10

  The present invention relates to new CGRP-antagonists of general formula I wherein U, V, X, Y, R 1 , R 2 and R 3 are defined as stated hereinafter, the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates, the mixtures thereof and the salts thereof and the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, pharmaceutical compositions containing these compounds, their use and processes for preparing them.

  本发明涉及一般式I的新的CGRP拮抗剂，其中U、V、X、Y、R1、R2和R3如下所述定义，其互变异构体、同分异构体、对映异构体、水合物、混合物及其盐和盐的水合物，特别是其与无机或有机酸或碱的生理上可接受的盐，含有这些化合物的药物组合物，其用途以及制备它们的过程。
• [EN] SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS<br/>[FR] IMIDAZO[1,2-B]PYRIDAZINES SUBSTITUÉES, IMIDAZO[1,5-B]PYRIDAZINES SUBSTITUÉES, COMPOSÉS APPARENTÉS ET LEUR UTILISATION DANS LE TRAITEMENT DE TROUBLES MÉDICAUX
  申请人：LYSOSOMAL THERAPEUTICS INC

  公开号：WO2017192930A1

  公开（公告）日：2017-11-09

  The invention provides substituted imidazo[1,2-b]pyridazine compounds, substituted imidazo[1,5-b]pyridazine compounds, related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted imidazo[1,2-b]pyridazine compounds described herein include substituted imidazo[1,2-b]pyridazine-3-carboxamide compounds and variants thereof.

  该发明提供了替代咪唑并[1,2-b]吡啶嗪化合物，替代咪唑并[1,5-b]吡啶嗪化合物，相关化合物，含有这些化合物的组合物，医疗工具包，以及使用这些化合物和组合物治疗医疗疾病（例如高雪氏病、帕金森病、Lewy体病、痴呆症或多系统萎缩）的方法，适用于患者。这里描述的示例替代咪唑并[1,2-b]吡啶嗪化合物包括替代咪唑并[1,2-b]吡啶嗪-3-羧酰胺化合物及其变体。
• 3-Pyridazinylnitrenes and 2-Pyrimidinylnitrenes
  作者：Sebastian Torker、David Kvaskoff、Curt Wentrup

  DOI：10.1021/jo4027897

  日期：2014.2.21

  Mild flash vacuum thermolysis of tetrazolo[1,5-b]pyridazines 8T generates small amounts of 3-azidopyridazines 8A (8aA, IR 2145, 2118 cm–1; 8bA, 2142 cm–1). Photolysis of the tetrazoles/azides 8T/8A in Ar matrix generates 3-pyridazinylnitrenes 9, detected by ESR spectroscopy (9a: D/hc = 1.006; E/hc = 0.003 cm–1). Cyanovinylcarbenes 11, derived from 4-diazobut-2-enenitriles 10, are also detected by ESR

  四唑并[1,5- b ]哒嗪8T的温和快速真空热解会生成少量的3-叠氮基哒嗪8A（8aA，IR 2145，2118 cm –1；8bA，2142 cm –1）。在Ar基质中对四唑/叠氮化物8T / 8A进行光解会生成3-吡啶并氮杂氮基9，通过ESR光谱法检测到（9a：D / hc = 1.006；E / hc = 0.003 cm –1）。Cyanovinylcarbenes 11，由4- diazobut -2- enenitriles衍生10，也可以通过ESR光谱法检测（11a：D / hc = 0.362；E / hc = 0.021 cm –1）。卡宾11重排为氰基亚勒烯12和3-氰基环丙烯13。在8的光解中未观察到三氮杂七庚烯20。在254 nm的Ar矩阵中对四唑并[1,5- a ]嘧啶/ 2-叠氮基吡啶18T / 18A进行光解可得到2-嘧啶基亚硝酸19，可通过ESR，UV和IR光谱法观察到（19a：ESR：D